The publisher explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (20 May 2020)
Model updates (6 August 2019)
Snapshot
- Overview: Boehringer Ingelheim will see near-term growth, but will see long-term revenue declines because of fewer NMEs in its late-stage pipeline compared to its peers.
- Key themes: [1] Upcoming label expansions for Jardiance should help to sustain recent robust revenue trends [2] Ofev should see continued growth in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease associated with systemic sclerosis (SSc-ILD) [3] Boehringer Ingelheim will see royalties from Skyrizi, which has already become a blockbuster product for AbbVie.
Model updates (20 May 2020)
- Jardiance forecast adjusted higher
- Glyxambi forecast removed due to Boehringer not providing brand-level revenue performance
- Stiolto forecast removed due to Boehringer not providing brand-level revenue performance.
Model updates (6 August 2019)
- Ofev forecast adjusted higher due to market share gains within IPF
- Jardiance forecast adjusted higher due to strong growth.
Table of Contents
Company Background
Company Forecast
Company Profile
Clinical Trial Overview
